For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?

Saved in:
Bibliographic Details
Published in:La revue de medecine interne 2021-05, Vol.42 (5), p.369-370
Main Authors: Lanthier, L, Langlois, M-F, Plourde, M-É, Cauchon, M
Format: Article
Language:eng ; fre
Subjects:
Body Weight
Comorbidity
Diabetes Mellitus, Type 2 - drug therapy
Glucagon-Like Peptides
Humans
Hypoglycemic Agents - therapeutic use
Life Style
Obesity - complications
Obesity - epidemiology
Obesity - therapy
Overweight - complications
Overweight - epidemiology
Overweight - therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 370
container_issue 5
container_start_page 369
container_title La revue de medecine interne
container_volume 42
creator Lanthier, L
Langlois, M-F
Plourde, M-É
Cauchon, M
description
doi_str_mv 10.1016/j.revmed.2021.03.334
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2511896449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2511896449</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-37dfb02cdf3d27fe1308d9b1b672924a186482a7438afbb54f915757413097c43</originalsourceid><addsrcrecordid>eNpNkUuLFDEUhYMgzjj6D0Tu0oVd5lWvlcgwowMDbnTd5HHTlaaqUiapbvqXuzXdjjKLkOSe7xwOXELeMVoxyppP-yriYUJbccpZRUUlhHxBrlnbdBvBOL8ir1PaU0oL3b8iV0J0outrek1-34cIQWNCWFT2OOcEZeLK-f8_DgFURAgHjEf0uyGDmi0M6oDlASqlYLzKaMGEKUTtrc-njzCEIyTl8AKjc2iyLw6fIOGkduOavS1iOruWkm_h6PMAy6gM6nAWzuF2v84mQw4weocpn8YSMWeMh9LNh_lStZhX4-cd6GBP8KxjyAOe5fFSD8tkCcWdPr8hL50aE759um_Iz_u7H7ffNo_fvz7cfnncLIw3eSNa6zTlxjpheeuQCdrZXjPdtLznUrGukR1XrRSdclrX0vWsbutWFrBvjRQ35MPf3CWGX2vpv518MjiOasawpi2vGev6Rsq-oO-f0FWXXW6X6CcVT9t_yxJ_APHjnKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2511896449</pqid></control><display><type>article</type><title>For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?</title><source>Elsevier</source><creator>Lanthier, L ; Langlois, M-F ; Plourde, M-É ; Cauchon, M</creator><creatorcontrib>Lanthier, L ; Langlois, M-F ; Plourde, M-É ; Cauchon, M</creatorcontrib><identifier>EISSN: 1768-3122</identifier><identifier>DOI: 10.1016/j.revmed.2021.03.334</identifier><identifier>PMID: 33838950</identifier><language>eng ; fre</language><publisher>France</publisher><subject>Body Weight ; Comorbidity ; Diabetes Mellitus, Type 2 - drug therapy ; Glucagon-Like Peptides ; Humans ; Hypoglycemic Agents - therapeutic use ; Life Style ; Obesity - complications ; Obesity - epidemiology ; Obesity - therapy ; Overweight - complications ; Overweight - epidemiology ; Overweight - therapy</subject><ispartof>La revue de medecine interne, 2021-05, Vol.42 (5), p.369-370</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33838950$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanthier, L</creatorcontrib><creatorcontrib>Langlois, M-F</creatorcontrib><creatorcontrib>Plourde, M-É</creatorcontrib><creatorcontrib>Cauchon, M</creatorcontrib><title>For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?</title><title>La revue de medecine interne</title><addtitle>Rev Med Interne</addtitle><subject>Body Weight</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glucagon-Like Peptides</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Life Style</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Obesity - therapy</subject><subject>Overweight - complications</subject><subject>Overweight - epidemiology</subject><subject>Overweight - therapy</subject><issn>1768-3122</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkUuLFDEUhYMgzjj6D0Tu0oVd5lWvlcgwowMDbnTd5HHTlaaqUiapbvqXuzXdjjKLkOSe7xwOXELeMVoxyppP-yriYUJbccpZRUUlhHxBrlnbdBvBOL8ir1PaU0oL3b8iV0J0outrek1-34cIQWNCWFT2OOcEZeLK-f8_DgFURAgHjEf0uyGDmi0M6oDlASqlYLzKaMGEKUTtrc-njzCEIyTl8AKjc2iyLw6fIOGkduOavS1iOruWkm_h6PMAy6gM6nAWzuF2v84mQw4weocpn8YSMWeMh9LNh_lStZhX4-cd6GBP8KxjyAOe5fFSD8tkCcWdPr8hL50aE759um_Iz_u7H7ffNo_fvz7cfnncLIw3eSNa6zTlxjpheeuQCdrZXjPdtLznUrGukR1XrRSdclrX0vWsbutWFrBvjRQ35MPf3CWGX2vpv518MjiOasawpi2vGev6Rsq-oO-f0FWXXW6X6CcVT9t_yxJ_APHjnKw</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Lanthier, L</creator><creator>Langlois, M-F</creator><creator>Plourde, M-É</creator><creator>Cauchon, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202105</creationdate><title>For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?</title><author>Lanthier, L ; Langlois, M-F ; Plourde, M-É ; Cauchon, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-37dfb02cdf3d27fe1308d9b1b672924a186482a7438afbb54f915757413097c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>Body Weight</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glucagon-Like Peptides</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Life Style</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Obesity - therapy</topic><topic>Overweight - complications</topic><topic>Overweight - epidemiology</topic><topic>Overweight - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanthier, L</creatorcontrib><creatorcontrib>Langlois, M-F</creatorcontrib><creatorcontrib>Plourde, M-É</creatorcontrib><creatorcontrib>Cauchon, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>La revue de medecine interne</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanthier, L</au><au>Langlois, M-F</au><au>Plourde, M-É</au><au>Cauchon, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?</atitle><jtitle>La revue de medecine interne</jtitle><addtitle>Rev Med Interne</addtitle><date>2021-05</date><risdate>2021</risdate><volume>42</volume><issue>5</issue><spage>369</spage><epage>370</epage><pages>369-370</pages><eissn>1768-3122</eissn><cop>France</cop><pmid>33838950</pmid><doi>10.1016/j.revmed.2021.03.334</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier EISSN: 1768-3122
ispartof La revue de medecine interne, 2021-05, Vol.42 (5), p.369-370
issn 1768-3122
language eng ; fre
recordid cdi_proquest_miscellaneous_2511896449
source Elsevier
subjects Body Weight
Comorbidity
Diabetes Mellitus, Type 2 - drug therapy
Glucagon-Like Peptides
Humans
Hypoglycemic Agents - therapeutic use
Life Style
Obesity - complications
Obesity - epidemiology
Obesity - therapy
Overweight - complications
Overweight - epidemiology
Overweight - therapy
title For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A08%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=For%20obese%20patients%20or%20for%20patients%20who%20are%20overweight%20and%20have%20an%20associated%20comorbidity,%20how%20safe%20and%20effective%20is%20semaglutide%20as%20compared%20with%20placebo%20as%20an%20adjunct%20to%20lifestyle%20intervention%20for%20reducing%20body%20weight%20and%20other%20related%20end%20points?&rft.jtitle=La%20revue%20de%20medecine%20interne&rft.au=Lanthier,%20L&rft.date=2021-05&rft.volume=42&rft.issue=5&rft.spage=369&rft.epage=370&rft.pages=369-370&rft.eissn=1768-3122&rft_id=info:doi/10.1016/j.revmed.2021.03.334&rft_dat=%3Cproquest_pubme%3E2511896449%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p126t-37dfb02cdf3d27fe1308d9b1b672924a186482a7438afbb54f915757413097c43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2511896449&rft_id=info:pmid/33838950&rfr_iscdi=true